常山药业(300255) - 2020 Q3 - 季度财报

Financial Performance - Operating revenue for the reporting period was ¥627,763,709.10, representing a year-on-year increase of 19.40%[8] - Net profit attributable to shareholders of the listed company was ¥73,967,718.67, up 4.24% year-on-year[8] - Basic earnings per share for the reporting period was ¥0.08, unchanged from the previous year[8] - The company reported a net profit of ¥1,377,130,848.91, up from ¥1,184,663,530.00, reflecting an increase of approximately 16.3% in retained earnings[44] - Total operating revenue for the current period reached ¥627,763,709.10, an increase from ¥525,781,826.50 in the previous period, representing a growth of approximately 19.4%[53] - Net profit for the current period was ¥73,643,135.86, compared to ¥70,301,795.02 in the previous period, reflecting a growth of approximately 3.3%[59] - The company reported a total comprehensive income of ¥59,423,573.09 for the current period, down from ¥71,612,311.36 in the previous period[62] - The total profit for the current period was ¥261,965,048.70, an increase of 15.8% compared to ¥226,204,755.78 in the previous period[80] Assets and Liabilities - Total assets at the end of the reporting period reached ¥4,619,090,027.38, an increase of 17.16% compared to the end of the previous year[8] - Non-current assets totaled ¥1,500,728,079.13, compared to ¥1,408,374,015.80, reflecting an increase of about 6.5%[41] - Current liabilities rose to ¥1,495,085,908.86 from ¥1,188,124,516.75, marking an increase of approximately 26%[41] - The company's total liabilities reached ¥1,802,944,043.11, up from ¥1,220,317,707.40, reflecting a growth of about 47.7%[41] - Total liabilities increased to ¥1,857,496,020.17 from ¥1,264,625,864.56, marking a rise of approximately 47%[51] - The equity attributable to shareholders increased to ¥2,809,960,907.54 from ¥2,714,925,009.49, a rise of approximately 3.5%[44] Cash Flow - The net cash flow from operating activities was ¥13,995,074.21, a decrease of 70.22% compared to the same period last year[8] - Cash flow from operating activities showed a net outflow of ¥402,681,670.92, worsening from a net outflow of ¥195,091,069.12 in the previous period[86] - Cash inflow from financing activities totaled 2,317,391,878.90, significantly up from 1,164,522,532.50 in the prior period, reflecting increased financing efforts[96] - The cash outflow from financing activities was 1,888,848,097.38, compared to 1,162,896,313.14 previously, showing a rise in cash used for financing[96] Shareholder Information - The total number of common shareholders at the end of the reporting period was 30,949[13] - The largest shareholder, Gao Shuhua, holds 35.69% of the shares, totaling 333,644,728 shares[13] Expenses - Total operating costs amounted to ¥543,883,902.09, up from ¥446,080,632.07, indicating an increase of about 21.9%[56] - Research and development expenses decreased to ¥27,992,355.94 from ¥38,973,977.21, a reduction of approximately 28.2%[56] - Sales expenses increased to ¥294,566,909.48 from ¥260,519,818.46, reflecting a rise of about 13%[56] - Financial expenses increased by 40.92% compared to the same period last year, mainly due to increased interest expenses and fees[24] Inventory and Receivables - Accounts receivable financing decreased by 53.93% compared to the beginning of the period, mainly due to the endorsement transfer of bank acceptance bills[24] - Prepayments increased by 31.11% compared to the beginning of the period, primarily due to increased prepayments for raw materials and marketing expenses[24] - Other receivables increased by 161.91% compared to the beginning of the period, mainly due to the increase in procurement deposits for biological raw materials[24] - Inventory increased by 33.44% compared to the beginning of the period, primarily due to rising raw material prices and increased procurement of biological raw materials[24] Strategic Developments - There were no significant changes in the company's strategy or new product developments mentioned in the report[8]